Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • From the Analyst's Couch
  • Published:

Avoiding premature licensing

Nature Reviews Drug Discovery volume 5, pages 985–986 (2006)Cite this article

A Corrigendum to this article was published on 01 February 2007

Since its inception, the biotechnology industry has faced the challenge of financing the tremendously costly activities of novel drug development. Historically, venture capital and government grants have been the primary funding source for start-up and discovery-stage drug development efforts, while the public equity and debt markets, and large pharma's chequebook, have been instrumental in the financing of late-stage clinical programmes that are significantly less risky. Despite this relatively stable funding environment for very early and very late-stage programmes, mid-stage development programmes — those that are undergoing Phase I and II clinical trials — have been stuck in what amounts to a financial no-man's land.

Timing and value

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Value of biotech out-licensing deals.
Figure 2: Example of a collaborative development financing structure.
Figure 3: Illustrative value creation through collaborative development financing.

Author information

Authors and Affiliations

  1. Managing Director and Sam Hall is an Associate at Symphony Capital LLC, 875 Third Avenue, 18th Floor, New York, 10022, New York, USA

    Mark Kessel & Sam Hall

Authors
  1. Mark Kessel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sam Hall
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

As a result of the financings completed by Symphony Capital Partners and its affiliates listed in Table 1, Mark Kessel and Sam Hall have certain economic interests in the biotech companies listed therein and the respective collaborative partnering companies developing those indications.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kessel, M., Hall, S. Avoiding premature licensing. Nat Rev Drug Discov 5, 985–986 (2006). https://doi.org/10.1038/nrd2203

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd2203

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing